Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Pan Afr Med J ; 45: 77, 2023.
Artigo em Francês | MEDLINE | ID: mdl-37663626

RESUMO

In case of dehydration, lithium can cause acute intoxication. This picture is mainly manifested by neurological disorders that can go as far as coma, digestive disorders, hydroelectrolytic disorders, and cardiovascular disorders. We report the case of a patient followed for bipolar disorder for 20 years and treated with lithium for 14 years and who presented an acute lithium intoxication resulting from a diabetes insipidus. Our objective is to underline the importance of good hydration and strict monitoring of lithium levels especially in situations favouring dehydration, notably the polyuria of diabetes insipidus.


Assuntos
Transtorno Bipolar , Diabetes Insípido Nefrogênico , Diabetes Insípido , Diabetes Mellitus , Humanos , Diabetes Insípido Nefrogênico/induzido quimicamente , Diabetes Insípido Nefrogênico/diagnóstico , Lítio , Desidratação , Transtorno Bipolar/tratamento farmacológico
2.
Clin Immunol ; 161(2): 217-24, 2015 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-26277548

RESUMO

It is unknown if cholecalciferol is able to modify defects in regulatory T cells (Tregs) in type 1 diabetes (T1D). In this randomized, double-blind, placebo controlled trial 30 young patients with new-onset T1D were assigned to cholecalciferol (70IU/kgbodyweight/day) or placebo for 12months. Tregs were determined by FACS-analysis and functional tests were assessed with ex vivo suppression co-cultures at months 0, 3, 6 and 12. Suppressive capacity of Tregs increased (p<0.001) with cholecalciferol from baseline (-1.59±25.6%) to 3 (30.5±39.4%), 6 (44.6±23.8%) and 12months (37.2±25.0%) and change of suppression capacity from baseline to 12months was significantly higher (p<0.05) with cholecalciferol (22.2±47.2%) than placebo (-16.6±21.1%). Serum calcium and parathormone stayed within normal range. This is the first study, which showed that cholecalciferol improved suppressor function of Tregs in patients with T1D and vitamin D could serve as one possible agent in the development of immunomodulatory combination therapies for T1D.


Assuntos
Colecalciferol/uso terapêutico , Diabetes Mellitus Tipo 1/tratamento farmacológico , Suplementos Nutricionais , Linfócitos T Reguladores/efeitos dos fármacos , Adolescente , Peptídeo C/sangue , Criança , Colecalciferol/administração & dosagem , Colecalciferol/sangue , Diabetes Mellitus Tipo 1/sangue , Diabetes Mellitus Tipo 1/imunologia , Método Duplo-Cego , Jejum/sangue , Feminino , Humanos , Masculino , Projetos Piloto , Estudos Prospectivos , Linfócitos T Reguladores/imunologia , Fatores de Tempo , Resultado do Tratamento , Vitaminas/administração & dosagem , Vitaminas/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA